The pension played a "combination fist"; Kehua may have the risk of delisting; the new crown virus tested a new move

Photo/Pexels

Pension

The personal pension account is coming, and the annual payment limit is 12,000 yuan

On April 21, the General Office of the State Council issued the Opinions on Promoting the Development of Individual Pensions (hereinafter referred to as the Opinions), proposing that the individual pension should be implemented in an individual account system, and the contributions should be fully borne by the individual participants and fully accumulated; the upper limit of the annual payment of personal pensions by participants is 12,000 yuan.

In terms of account capital investment methods, personal pensions can be used to purchase financial products such as bank wealth management, savings deposits, commercial pension insurance, and public funds that meet the regulations, and participants can choose independently. After the death of a participant, the assets in his or her personal pension fund account can be inherited.

According to the Opinions, workers who participate in the basic old-age insurance for urban workers or the basic old-age insurance for urban and rural residents in China may participate in the individual pension system.

This system will be implemented step by step in combination with the actual situation, and some cities will be selected to try it out for one year first, and then gradually roll it out.

The Ministry of Public Security has deployed a special action to crack down on and rectify pension fraud

The National Public Security Organs Special Action Deployment Meeting to Combat and Rectify Pension Fraud was held on April 19. The Ministry of Public Security demanded that, in the name of providing "old-age services," investing in "old-age projects," selling "old-age products," declaring "housing for the aged," handling "endowment insurance," and carrying out "old-age assistance," it is necessary to carry out fraud, fund-raising fraud, illegal absorption of public deposits, organization and leadership of pyramid schemes, contract fraud, the manufacture and sale of counterfeit and shoddy goods, and the production, sale, and provision of counterfeit and inferior drugs, and other illegal and criminal activities that infringe on the property rights and interests of the elderly, and thoroughly crack down on tackling tough cases.

The Ministry of Public Security demanded that the flow of criminal suspects' funds should be investigated to the end, and all efforts should be made to recover the stolen goods and recover the losses, so as to minimize the losses of the victims.

It is also imperative to widely publicize typical cases of pension fraud and crimes, expose criminal "routine" methods, and improve the ability of the elderly to recognize fraud and prevent fraud.

It is understood that since 2017, public security organs across the country have cracked more than 4,500 cases of pension fraud and arrested more than 11,000 criminal suspects.

market

Mindray Medical handed over the transcript, less than the market expectations?

On the evening of April 19, Mindray Medical, a leader in medical equipment, announced its 2021 annual report. In 2021, the company achieved operating income of 25.27 billion yuan, an increase of 20.18% year-on-year; and achieved a net profit of 7.85 billion yuan, an increase of 20.04% year-on-year.

On the same day, Mindray Medical also announced the first quarter report of 2022, the company achieved operating income of 6.943 billion yuan, an increase of 20.1% year-on-year; achieved a net profit of 2.072 billion yuan after deduction of non-attributable mother, an increase of 22.2% year-on-year.

However, on April 20, Mindray Medical fell 8.71%, and its market value evaporated by 34.1 billion yuan. Obviously, despite the solid performance, the market does not recognize it.

Some analysts believe that from the perspective of the past five years, Mindray Medical Q1 and Q4 are generally small quarters of performance, but almost the profit side is growing synchronously, and Q4 in 2021 is significantly lower than the level of this year's Q1, which is obviously less than expected. In addition, although Mindray's 2022Q1 revenue and profit side increased by more than 20% year-on-year, the net operating cash flow did not increase with net profit, but decreased by 21.68% year-on-year, which to a certain extent indicates that the company's ability to collect money has declined, and may also be affected by the epidemic.

Kehua Bio may have the risk of delisting, and the subsidiary will not cooperate with the annual report audit

On the evening of April 20, Kehua Bio announced that the senior management of the holding subsidiary Tianlong Company refused to cooperate with the accounting firm hired by Kehua Bio to carry out the 2021 annual audit work, and refused to provide important information such as the subsidiary's 2021 annual financial books, which may lead to the company's 2021 annual financial report being issued with an audit report that "cannot express an opinion".

According to the Rules Governing the Listing of Stocks on the Shenzhen Stock Exchange, Kehua Bio's shares may be subject to delisting risk warnings.

On April 21, Kehua Bio fell to a halt at 11.69 yuan / share, and the stock price hit a new low in the year.

Founded in 1981, Kehua Bio is the first professional company in China to be listed on the Shenzhen Stock Exchange. The company's main business covers four major areas, such as in vitro diagnostic reagents, medical testing instruments, inspection information technology, and vacuum blood collection systems. In July 2021, the company's new coronavirus mutation nucleic acid detection kit (fluorescent PCR method) was shortlisted for export "white list".

R&D

The new coronavirus tested a new pattern, breathing samples to one

On April 14, local time, the official website of the U.S. Food and Drug Administration (FDA) released a message saying that the first device to be tested for new crown through breath samples was authorized for emergency use (EUA).

To put it bluntly, this test can provide results in less than three minutes. The instrument that performed the test was the size of a suitcase and could detect five volatile organic compounds associated with COVID-19 infection in the gas exhaled by the person being tested.

This is also the first time after nucleic acid detection and antigen detection that the new crown test through breath samples has been approved, and the FDA has evaluated it, which is another new case of rapid innovation of new crown testing. Nucleic acid testing and antigen testing require nasopharyngeal samples.

The U.S. FDA notes that sample collection and analysis of this test can be performed in the same environment, such as hospitals and other mobile testing sites. The test is carried out by qualified and trained personnel.

"Unexplained acute hepatitis in children" in many countries

Recently, many countries around the world have reported a number of cases of severe acute hepatitis in children, which has aroused market concern.

On April 19, local time, the European Centre for Disease Control and Prevention (ECDC) released a message saying that cases of childhood acute hepatitis of unknown origin were recorded in the United Kingdom, France, Spain, Ireland, Denmark, the Netherlands and other countries.

Of these, the total number of cases of hepatitis of unknown origin in young children found in the UK alone has reached 108; Spain has also reported five cases, of which three patients are between the ages of 22 months and 13 years; and the US health department has identified nine cases of hepatitis of unknown origin, between the ages of 1 and 6, two of whom even need liver transplants; Two children under the age of 10 who are suspected to have rare unexplained acute hepatitis are under investigation at the University Hospital of Lyon, France.

To date, no deaths have been reported in these cases, with the main symptoms including jaundice, diarrhea, vomiting and abdominal pain.

For a large number of cases of hepatitis of unknown origin, the World Health Organization (WHO), ECDC issued an alert. The WHO said in its latest report that laboratories are analyzing the causes of acute hepatitis in these children of unknown origin, and no known hepatitis virus has been detected at present, but in some cases the new coronavirus (SARS-CoV-2) or adenovirus (Adenovirus) has been detected.

On April 20, according to media reports, Jean-Marc Sabatier, director of research at the French National Academy of Sciences, said that preliminary studies have shown that the acute hepatitis may be caused by variants or sub-variants of the new crown virus, such as Omicron, XD, XE, etc., and that liver cells have ACE2 receptors on their surfaces, which is the target of the new coronavirus spike protein and vaccine spike protein.

The ECDC noted that investigations continue in all countries that have documented cases of hepatitis in children, and the exact cause of hepatitis in children remains unknown.